National Cancer Center, Korea

Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism

CollaboratorPhase 4Not yet recruiting20262,300 people1 Oct 2026clinicaltrials.gov

NCT05827523

Phase 3Recruiting2023520 people25 Apr 2023clinicaltrials.gov

NCT04214990

Phase 3Recruiting20201,700 people2 Jan 2020clinicaltrials.gov

NCT03497702

Phase 2Status unknown2017114 people13 Apr 2018clinicaltrials.gov

NCT03243851

CollaboratorPhase 2Completed201681 people9 Aug 2017clinicaltrials.gov

NCT02979223

Phase 2Completed2016142 people1 Dec 2016clinicaltrials.gov

NCT01939418

Phase 1/2Terminated201323 people11 Sept 2013clinicaltrials.gov

NCT01441349

Phase 2Status unknown2011192 people27 Sept 2011clinicaltrials.gov

NCT01198665

CollaboratorPhase 1/2Completed201046 people10 Sept 2010clinicaltrials.gov

NCT01159327

Phase 2Terminated201013 people9 Jul 2010clinicaltrials.gov

NCT01156545

Phase 2Completed201068 people5 Jul 2010clinicaltrials.gov

NCT01003964

Phase 2Completed2009289 people29 Oct 2009clinicaltrials.gov

NCT01002443

Phase 2Completed2003190 people27 Oct 2009clinicaltrials.gov

NCT00980603

Phase 2Status unknown2008144 people21 Sept 2009clinicaltrials.gov

NCT00915382

CollaboratorPhase 3Completed2009625 people8 Jun 2009clinicaltrials.gov

NCT00620269

Phase 2Status unknown2008212 people21 Feb 2008clinicaltrials.gov

NCT00532454

Phase 2Terminated200621 people20 Sept 2007clinicaltrials.gov

NCT00455936

Phase 3Completed2005315 people4 Apr 2007clinicaltrials.gov

NCT00452881

Phase 2Status unknown2006151 people28 Mar 2007clinicaltrials.gov

NCT00452634

Phase 2Completed200662 people27 Mar 2007clinicaltrials.gov

Consecutive Negative Screening Tests for Ovarian Cancer: A Reliable Basis for Reassurance of Low Ovarian Cancer Mortality Risk?

NCC-2310530, 231050023 Sept 2026api.crossref.org